Overview
At Tekton Research’s Yukon, OK site, Principal Investigator Dr. Robert Lockwood delivered standout performance in a Phase 2 migraine treatment study: meeting enrollment goals early, maintaining 100% patient retention, and achieving one of the sponsor’s highest eDiary compliance rates across all participating sites. His team’s performance not only exceeded expectations but also earned the site an invitation to participate in the upcoming Phase 3 study, where eDiary adherence is a critical success factor.
Challenge
Phase 2 migraine studies can be particularly demanding. Patients must consistently report daily symptoms and medication use via electronic diaries (eDiaries), requiring strong engagement and oversight. For sponsors, maintaining high compliance rates is essential for data integrity, yet it’s one of the most common pitfalls in migraine research. In addition, the Yukon site faced tight startup timelines and the need to enroll qualified participants quickly without sacrificing data quality or patient experience.
Solutions
Key Metrics
(Receipt to submission)
Dr. Lockwood and his Yukon team approached this study with meticulous planning and coordination. From rapid regulatory turnaround (1.5 days from reg receipt to submission) to first patient first visit within 48 hours of activation, every milestone reflected the site’s operational precision.
With Tekton’s centralized regulatory, contracting, and start-up infrastructure, Dr. Lockwood’s site had the resources and streamlined systems needed to move quickly. Real-time visibility into study progress through Tekton’s operational dashboards enabled continuous monitoring of compliance and enrollment performance.
The team prioritized communication and education, ensuring participants fully understood the eDiary process and study requirements before randomization. Continuous check-ins and proactive support from site staff drove 100% retention and near-perfect eDiary completion—critical metrics that reinforced the reliability of the site’s data.
Results
Tekton's Yukon site met its enrollment goal ahead of schedule, achieved full retention, and delivered some of the strongest eDiary compliance results of the study—outperforming peer sites and earning high marks from the sponsor’s clinical team. The site’s consistency, speed, and quality of data solidified its selection for the Phase 3 trial, where Tekton and Dr. Lockwood will continue to build on this momentum. The Yukon, OK site’s performance reflects Tekton’s core strengths: disciplined execution, physician-led engagement, and operational excellence.
